Skip to main content
. 2024 Jan 4;10(3):335–341. doi: 10.1001/jamaoncol.2023.5791

Table 2. Treatment-Related Adverse Events for All 40 Patients.

Event No. (%)
Grade 1 Grade 2 Grade 3 Grade 4
Diarrhea 20 (50) 10 (25) 3 (7.5) 0
Palmar-plantar erythrodysesthesia syndrome 11 (27.5) 8 (20) 1 (2.5) 0
Nausea 17 (42.5) 0 1 (2.5) 0
Anorexia 15 (37.5) 1 (2.5) 0 0
Vomiting 13 (32.5) 2 (5) 1 (2.5) 0
Fatigue 12 (30) 2 (5) 0 0
Anemia 12 (30) 1 (2.5) 1 (2.5) 0
Blood bilirubin conjugated level increased 11 (27.5) 0 0 0
Blood bilirubin unconjugated level increased 11 (27.5) 0 0 0
Lymphocyte cell count decreased 9 (22.5) 0 0 0
Alopecia 8 (20) 0 0 0
Weight loss 6 (15) 2 (5) 0 0
Headache 6 (15) 1 (2.5) 0 0
White blood cell count decreased 4 (10) 1 (2.5) 1 (2.5) 0
Alanine aminotransferase level increased 4 (10) 2 (5) 0 0
Creatinine level increased 5 (12.5) 1 (2.5) 0 0
Aspartate aminotransferase level increased 5 (12.5) 1 (2.5) 0 0
Dizziness 4 (10) 1 (2.5) 0 0
Hypertriglyceridemia 5 (12.5) 0 0 0
Hypokalemia 4 (10) 0 0 1 (2.5)
Intracranial radiation necrosis 4 (10) 0 0 0
Radiation dermatitis 3 (7.5) 1 (2.5) 0 0
Neutrophil count decreased 3 (7.5) 1 (2.5) 0 0
Gamma-glutamyl transpeptidase increased 4 (10) 0 0 0
Pruritus 3 (7.5) 0 0 0
Rash 3 (7.5) 0 0 0
Pigmentation disorder 1 (2.5) 1 (2.5) 0 0
Platelet count decreased 2 (5) 0 0 0
Dyspepsia 1 (2.5) 1 (2.5) 0 0
Mucositis oral 2 (5) 0 0 0
Acute kidney injury 0 0 1 (2.5) 0